サンプル依頼リスト カート
  • English
  • Korean
表紙：尋常性乾癬治療の世界市場-2023年～2030年
市場調査レポート
商品コード
1374831

尋常性乾癬治療の世界市場-2023年～2030年

Global Plaque Psoriasis Treatment Market - 2023-2030

出版日
ページ情報
英文 187 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
尋常性乾癬治療の世界市場-2023年～2030年
出版日: 2023年11月01日
発行: DataM Intelligence
ページ情報: 英文 187 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

概要

尋常性乾癬は、細胞の増殖が非常に速い、長期にわたる慢性の自己免疫性皮膚疾患です。尋常性乾癬の最も一般的なタイプで、皮膚にプラークと呼ばれる厚く鱗屑性の斑点が生じます。通常、新しい皮膚細胞は28～30日ごとに増殖します。しかし、尋常性乾癬の場合、新しい細胞は3～4日ごとに成長し、皮膚表面に移動します。古い細胞と入れ替わる新しい細胞の蓄積がプラークを生み出します。

さらに、尋常性乾癬は伝染性ではありません。尋常性乾癬には治療法はありませんが、個人差や症状の程度に応じて多くの治療法があります。外用療法としては、エモリエント剤、保湿剤、コルチコステロイド、角質溶解剤、コールタール、アントラリン、ビタミンD3アナログおよびカルシニューリン阻害剤の使用があります。外用薬を組み合わせて使用すると、薬剤を単独で使用した場合よりも効果的なことがあります。また、光線療法も治療に最もよく用いられています。

市場力学：促進要因

革新的薬剤の採用増加

尋常性乾癬に対する革新的な薬剤の採用が増加していることが、予測期間を通じて市場を牽引すると予想されます。革新的な薬剤の開発は、アンメットニーズに対応し、より良い疾患管理をもたらすことを目的としています。近年、バイオシミラーは尋常性乾癬の治療において最も注目されています。バイオシミラーは幅広い利点を提供し、参照生物製剤よりも研究開発がはるかに少なくて済むからです。バイオシミラーは製造コストがはるかに安いです。

例えば、2023年1月6日、アルボテックとテバ・ファーマシューティカルズは、アルボテックが提案したステラーラ（ウステキヌマブ）のバイオシミラーであるAVT04の生物製剤承認申請が米国食品医薬品局（FDA）に受理されたことを明らかにしました。ステラーラ（一般名：ウステキヌマブ）は、光線療法または全身療法が適応となる6歳以上の中等症から重症の尋常性乾癬患者を適応症としています。

さらに、FDA承認のような多くの規制当局の承認は、薬剤の安全性に対する患者の信頼を高めることにより、革新的な薬剤の採用を増加させます。例えば、2022年9月9日、ブリストル・マイヤーズスクイブ社は、米国食品医薬品局（FDA）より、全身療法または光線療法の候補である中等度から重度の尋常性乾癬の成人患者に対する治療薬として、ファースト・イン・クラスの経口選択的アロステリックチロシンキナーゼ2（TYK2）阻害薬であるSotyktu（deucravacitinib）が承認されたと発表しました。

また、免疫皮膚科学とリウマチ学のリーダーであるノバルティスは、2021年6月1日、全身療法または光線療法が適応となる6歳以上の小児患者における中等度から重度の尋常性乾癬の治療薬として、コセンティクス（一般名：セクキヌマブ）の米国食品医薬品局（FDA）の承認を取得しました。今回の承認は、米国において小児患者を対象とした初めての承認となります。

さらに、尋常性乾癬の有病率の増加、規制当局による承認の増加、先進治療の臨床試験の増加、認知度の向上と早期発見、新規薬剤や治療法の開発における技術進歩が、予測期間中に市場を牽引すると予想される要因となっています。

阻害要因

コルチコステロイド外用薬やその他の薬剤の大量投与に伴う合併症や副作用、光線療法にかかる高額な費用、より優れた正確な治療法の欠如などの要因が、市場の阻害要因になると予想されます。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 革新的医薬品の採用増加
    • 抑制要因
      • コルチコステロイドの使用に伴う副作用
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析
  • パイプライン分析
  • アンメットニーズ
  • 特許分析
  • ボリューム分析
  • DMIの見解

第6章 COVID-19分析

第7章 疾患タイプ別

  • 小プラーク乾癬
  • 大プラーク乾癬
  • 不安定性プラーク乾癬
  • 慢性プラーク乾癬

第8章 治療タイプ別

  • 局所薬
    • アントラリン
    • ロフルミラスト（ゾリーブ）
    • コルチコステロイド
    • タピナロフ（Vtama）
    • サリチル酸
    • コールタール
    • ジンクピリチオン
    • 局所エモリエント剤
    • その他
  • 全身薬
    • アシトレチン
    • シクロスポリン
    • メトトレキサート
  • 生物製剤
    • アダリムマブ（ヒュミラ）
    • ブロダルマブ（シリック）
    • セルトリズマブ・ペゴル（シムジア）
    • ドクラバシチニブ（ソティクトゥ）
    • エタネルセプト（エンブレル）
    • グセルクマブ（トレムフィア）
    • インフリキシマブ（アブソラ、インフレクトラ、レミケード）
    • その他
  • 光線療法
    • UVB光線照射
    • プソラレン＋紫外線A（PUVA）
    • エキシマレーザー療法
    • 在宅光線療法
    • その他
  • その他

第9章 販売チャネル別

  • 流通チャネル
    • 病院薬局
    • 小売薬局
    • オンライン薬局
  • エンドユーザー
    • 病院
    • 皮膚科クリニック
    • 光線療法センター
    • その他

第10章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋
  • 中東・アフリカ

第11章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第12章 企業プロファイル

  • Dermavant Sciences, Inc.
    • 会社概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な動向
  • Novartis AG
  • Pfizer Inc.
  • Mylan N.V.
  • Boehringer Ingelheim Pharmaceuticals, Inc.
  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • Lupin Pharmaceuticals, Inc.
  • AbbVie Inc.
  • Eli Lilly and Company

第13章 付録

目次
Product Code: PH7360

Overview

Plaque psoriasis also known as psoriasis vulgaris is a long-lasting and chronic autoimmune skin disease that causes cells to reproduce very quickly. It's the most common type of psoriasis that causes thick, scaly patches called plaques on the skin. Typically, new skin cells grow every 28 to 30 days. But in the case of plaque psoriasis, new cells grow and move to the skin's surface every three to four days. The buildup of new cells replacing old cells creates plaques.

Moreover, plaque psoriasis isn't contagious. There is no cure for plaque psoriasis, but many treatment options are available, depending on the individual and the severity of symptoms. Topical therapy includes the use of emollients and moisturizers, corticosteroids, keratolytics, coal tar, anthralin, vitamin D3 analogs and calcineurin inhibitors. A combination of topical agents is sometimes more effective than when the drugs are used alone. Phototherapy is also most commonly used in the treatment.

Market Dynamics: Drivers

Increasing adoption of innovative medications

The increasing adoption of innovative medications for plaque psoriasis is expected to drive the market over the forecast period. The development of innovative medications aims to address unmet needs and results in better disease management. In recent years, biosimilars are most focused in the treatment of plaque psoriasis, because biosimilars offers a wide range of benefits and require much less research and development than their reference biologics. Biosimilars are much cheaper to produce.

For instance, on January 06, 2023, Alvotech and Teva Pharmaceuticals cleared that the U.S. Food and Drug Administration (FDA) has accepted for review a Biologics License Application for AVT04, Alvotech's proposed biosimilar to Stelara (ustekinumab). STELARA (ustekinumab) is indicated for the treatment of patients 6 years or older with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.

Moreover, many regulatory approvals such as FDA approvals increase the adoption of innovative medications by boosting the trust in patients about the safety of the medications. For instance, on September 09, 2022, Bristol Myers Squibb released that the U.S. Food and Drug Administration (FDA) approved Sotyktu(deucravacitinib), a first-in-class, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Additionally, on June 1, 2021, Novartis, a leader in immuno-dermatology and rheumatology, cleared the U.S. Food and Drug Administration (FDA) approval of Cosentyx (secukinumab) for the treatment of moderate to severe plaque psoriasis in pediatric patients six years and older who are candidates for systemic therapy or phototherapy. This is the first approval for Cosentyx in a pediatric population in the US.

Further, the increasing prevalence of plaque psoriasis, rising regulatory approvals, increasing clinical trials for advanced therapies, increasing awareness and early detection and technological advancements in the development of novel drugs and therapies are the factors expected to drive the market over the forecast period.

Restraints

Factors such as complications and side effects associated with the high doses of topical corticosteroids and other drugs, the high cost of the treatment phototherapy and the lack of better and accurate treatment are expected to hamper the market.

Segment Analysis

The global plaque psoriasis treatment market is segmented based on disease type, treatment type, sales channel and region.

The topical medications segment accounted for approximately 41.1% of the plaque psoriasis treatment market share

The topical medications segment is expected to hold the largest market share over the forecast period. Usually, there is no cure for plaque psoriasis, but topical medications are considered first-line therapeutics based on the severity and symptoms. Various types of topical medications such as anthralin, roflumilast (zoryve), corticosteroids, tapinarof (VTAMA), salicylic acid, coal tar, zinc pyrithione and topical emollients are most commonly used for the treatment.

For instance, on May 24, 2022, Dermavant Sciences, a biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, cleared the U.S. Food and Drug Administration (FDA) approval of VTAMA (tapinarof) cream, 1%, an aryl hydrocarbon receptor agonist, indicated for the topical treatment of plaque psoriasis in adults. This approval makes VTAMA cream the first and only FDA-approved steroid-free topical medication in its class.

Moreover, on July 29, 2022, Arcutis Biotherapeutics, Inc. cleared the U.S. Food and Drug Administration (FDA) approval of the New Drug Application for ZORYVE (roflumilast) cream 0.3% for the treatment of plaque psoriasis, including intertriginous areas, in patients 12 years of age or older. The first and only topical phosphodiesterase-4 (PDE4) inhibitor approved for the treatment of plaque psoriasis, ZORYVE provides rapid clearance of psoriasis plaques and reduces itch in all affected areas of the body.

Further, their wide availability, acceptability, and, ease of application helps to hold the largest market share. The topical medications manage skin symptoms and have anti-inflammatory effects on the skin to clear psoriasis plaques. They include a class of medication called a corticosteroid. Although they are effective and fast-acting for better patient outcomes. In addition, their wide adoption also increases the demand for topical medications.

Geographical Analysis

North America accounted for approximately 40.1% of the market share

North America region is expected to hold the largest market share over the forecast period owing to the strong presence of major players and increasing adoption of novel medications. North America especially in the United States has a strong presence of major players such as pharmaceutical companies, biotechnology companies and medical device companies. This presence of major players actively performs in research activities for the development of more advanced and effective therapeutics for the treatment of plaque psoriasis.

For instance, on December 20, 2021, Amgen released the U.S. Food and Drug Administration (FDA) approval of Otezla (apremilast) for the treatment of adult patients with plaque psoriasis who are candidates for phototherapy or systemic therapy. With this expanded indication, Otezla is now the first and only oral treatment approved in adult patients with plaque psoriasis across all severities, including mild, moderate and severe.

Furthermore, due to the increasing prevalence of the condition, there is an increasing adoption of novel medications in the region. For instance, according to the National Psoriasis Foundation/USA, more than 8 million people in the U.S. have psoriasis. About eight in 10 people with psoriasis have plaque psoriasis. The increasing prevalence is increasing the demand for the adoption of novel therapeutics for the early management of the condition and associated severity for the better patient outcomes.

Competitive Landscape

The major global players in the plaque psoriasis treatment market include: Dermavant Sciences, Inc., Novartis AG, Pfizer Inc., Mylan N.V., Boehringer Ingelheim Pharmaceuticals, Inc., AstraZeneca PLC, Lupin Pharmaceuticals, Inc., Bristol-Myers Squibb Company, AbbVie Inc., Eli Lilly and Company and among others.

Key Developments

  • On May 28, 2022, UCB announced cleared the U.S. Food and Drug Administration (FDA) approval of extending the label for CIMZIA (certolizumab pegol) to include a new indication in adults with moderate-to-severe plaque psoriasis. CIMZIA is indicated for the treatment of adults with moderate-to-severe plaque psoriasis (PsO) who are candidates for systemic therapy or phototherapy. The approval makes CIMZIA the first Fc-free, PEGylated anti-TNF treatment option for this indication and marks the entry of UCB into immuno-dermatology, where a significant unmet need currently exists.
  • On May 25, 2022, Almirall S.A. launched Wynzora cream (50 µg/g calcipotriol and 0.5 mg/g betamethasone as dipropionate), developed for the topical treatment of mild to moderate plaque psoriasis in adults including scalp.

COVID-19 Impact Analysis

The COVID-19 pandemic significantly impacted the global plaque psoriasis treatment market. During the pandemic, many clinical trials were delayed or temporarily halted due to the redirected focus on the COVID-19 pandemic. This could have affected the development and approval timelines for new treatments or drugs in plaque psoriasis. The pandemic accelerated the adoption of telehealth services. Dermatologists and healthcare providers started offering virtual consultations, which could have influenced patients with plaque psoriasis to receive care and prescriptions. The pandemic also disrupted the supply chain of these treatment drugs globally.

Market Segmentation

By Disease Type

  • Small-Plaque Psoriasis
  • Large-Plaque Psoriasis
  • Unstable Plaque Psoriasis
  • Chronic Plaque Psoriasis

By Treatment Type

  • Topical Medications
    • Anthralin
    • Roflumilast (Zoryve)
    • Corticosteroids
    • Tapinarof (Vtama)
    • Salicylic Acid
    • Coal Tar
    • Zinc Pyrithione
    • Topical Emollients
    • Others
  • Systemic Drugs
    • Acitretin
    • Cyclosporine
    • Methotrexate
  • Biologics
    • Adalimumab (Humira)
    • Brodalumab (Siliq)
    • Certolizumab-Pegol (Cimzia)
    • Deucravacitinib (Sotyktu)
    • Etanercept (Enbrel)
    • Guselkumab (Tremfya)
    • Infliximab (Avsola, Inflectra, Remicade)
    • Others
  • Phototherapy
    • Exposure To UVB Light
    • Psoralen Plus Ultraviolet A (PUVA)
    • Excimer Laser Therapy
    • Home Phototherapy
    • Others
  • Others

By Sales Channel

  • Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • End-User
    • Hospitals
    • Dermatology Clinics
    • Phototherapy Centers
    • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa

Why Purchase the Report?

  • To visualize the global plaque psoriasis treatment market segmentation based on disease type, treatment type, sales channel and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development
  • Excel data sheet with numerous data points of plaque psoriasis treatment market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global plaque psoriasis treatment market report would provide approximately 61 tables, 59 figures, and 187 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Disease Type
  • 3.2. Snippet by Treatment Type
  • 3.3. Snippet by Sales Channel
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing Adoption of Innovative Medications
    • 4.1.2. Restraints
      • 4.1.2.1. Side Effects Associated with the Use of Corticosteroids
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Pipeline Analysis
  • 5.6. Unmet Needs
  • 5.7. Patent Analysis
  • 5.8. Volume Analysis
  • 5.9. DMI Opinion

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID
    • 6.1.2. Scenario During COVID
    • 6.1.3. Scenario Post COVID
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Disease Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 7.1.2. Market Attractiveness Index, By Disease Type
  • 7.2. Small-Plaque Psoriasis*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Large-Plaque Psoriasis
  • 7.4. Unstable Plaque Psoriasis
  • 7.5. Chronic Plaque Psoriasis

8. By Treatment Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 8.1.2. Market Attractiveness Index, By Treatment Type
  • 8.2. Topical Medications*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 8.2.3. Anthralin
    • 8.2.4. Roflumilast (Zoryve)
    • 8.2.5. Corticosteroids
    • 8.2.6. Tapinarof (Vtama)
    • 8.2.7. Salicylic Acid
    • 8.2.8. Coal Tar
    • 8.2.9. Zinc Pyrithione
    • 8.2.10. Topical Emollients
    • 8.2.11. Others
  • 8.3. Systemic Drugs
    • 8.3.1. Acitretin
    • 8.3.2. Cyclosporine
    • 8.3.3. Methotrexate
  • 8.4. Biologics
    • 8.4.1. Adalimumab (Humira)
    • 8.4.2. Brodalumab (Siliq)
    • 8.4.3. Certolizumab-Pegol (Cimzia)
    • 8.4.4. Deucravacitinib (Sotyktu)
    • 8.4.5. Etanercept (Enbrel)
    • 8.4.6. Guselkumab (Tremfya)
    • 8.4.7. Infliximab (Avsola, Inflectra, Remicade)
    • 8.4.8. Others
  • 8.5. Phototherapy
    • 8.5.1. Exposure To UVB Light
    • 8.5.2. Psoralen Plus Ultraviolet A (PUVA)
    • 8.5.3. Excimer Laser Therapy
    • 8.5.4. Home Phototherapy
    • 8.5.5. Others
  • 8.6. Others

9. By Sales Channel

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
    • 9.1.2. Market Attractiveness Index, By Sales Channel
  • 9.2. Distribution Channel*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 9.2.3. Hospital Pharmacies
    • 9.2.4. Retail Pharmacies
    • 9.2.5. Online Pharmacies
  • 9.3. End-User
    • 9.3.1. Hospitals
    • 9.3.2. Dermatology Clinics
    • 9.3.3. Phototherapy Centers
    • 9.3.4. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. UK
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Dermavant Sciences, Inc.*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. Novartis AG
  • 12.3. Pfizer Inc.
  • 12.4. Mylan N.V.
  • 12.5. Boehringer Ingelheim Pharmaceuticals, Inc.
  • 12.6. AstraZeneca PLC
  • 12.7. Bristol-Myers Squibb Company
  • 12.8. Lupin Pharmaceuticals, Inc.
  • 12.9. AbbVie Inc.
  • 12.10. Eli Lilly and Company

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us